United States · 
Who invested in Lindy Biosciences?
Lindy Biosciences's investors include Good Growth Capital, IAG Capital Partners and North Carolina Biotechnology Center.
United States · Series B startup
Who invested in Lindy Biosciences
Funding summaryUpdated 26 Oct 2026
$3.2Mraised across 1 round since 2022, from 1 source
- Latest round
- Series B, $3.2MMar 2022
- Investors
- 3
The rounds
- Mar 2022Series B$3.2M
Source recordedSEC filing: $3.3M sold, first sale Mar 2022
Founders and team
From Lindy Biosciences's own website and the SEC filings it signed: 5 on the team.
- Gary E. VinsonChief Operating Officer
- Neil JonesVP, Corporate Strategic Partnerships
- Deborah BitterfieldExecutive Officer, Director, Promoteri
- Karen LeVertDirector
- Omar FloresExecutive Officer, Directori
On the board, as filediJoel Whitley
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
This firm lists Lindy Biosciences as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Quick answers about Lindy Biosciences
How much has Lindy Biosciences raised?
Lindy Biosciences has raised $3.2M across 1 round since 2022.
When did Lindy Biosciences last raise?
Lindy Biosciences's most recent round was a Series B of $3.2M in Mar 2022.
What was Lindy Biosciences's biggest round?
Its most recent round, $3.2M in Mar 2022, is also its largest on record.
Who backed Lindy Biosciences first?
Lindy Biosciences's first round on record, in Mar 2022, was backed by Good Growth Capital, IAG Capital Partners and North Carolina Biotechnology Center.
What stage is Lindy Biosciences at?
Lindy Biosciences's latest named round is a Series B, in Mar 2022.
Where is Lindy Biosciences based?
Lindy Biosciences is based in the United States.
Companies like Lindy Biosciences
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.